Thiazolinedione treatment in PCOS an update

Gynecological Endocrinology

Volumn 26, Issue 11, 2010, Pages 791-803

  Glintborg, Dorte ^a   Andersen, Marianne ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bone mineral density; insulin; insulin sensitivity; metabolic syndrome; PCOS; pioglitazone; PPAR ; rosiglitazone; troglitazone

Indexed keywords

GROWTH HORMONE; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; TROGLITAZONE;

ADRENAL FUNCTION; ANOVULATION; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FERTILIZATION IN VITRO; GLUCOSE METABOLISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENAL GLANDS; BONE DENSITY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OVARY; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 77958005804     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.491572     Document Type: Review

References (104)

1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;1:19-25.
2. Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010;4:281-296.
3. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Position statement: glucose intolerance in polycystic ovary syndrome a position statement of the androgen excess society. J Clin Endocrinol Metab 2007;12:4546-4556.
4. Hojlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frosig C, Beck-Nielsen H, Wojtaszewski JF. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2008;2:357-366.
5. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen PE, Schousboe K, Hermann AP. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004;6:1570-1579.
6. Bjorntorp P. The android woman-a risky condition. J Intern Med 1996;2:105-110.
7. Azziz R, Carmina E, Dewailly D, Amanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;2:456-488.
8. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007; 2:317-322.
9. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053.
10. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 3:797-802.
11. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;6:2784-2791.
12. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003;6:753-759.
13. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;8:3835-3840.
14. Aigner E, Bachofner N, Klein K, De GC, Hohla F, Patsch W, Datz C. Retinol-binding protein 4 in polycystic ovary syndrome-association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab 2009;4: 1229-1235.
15. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006;6:1400-1407.
16. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with poly-cystic ovary syndrome: a randomized placebo-controlled study. Fertil Steril 2007;1:202-206.
17. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007;2:263-269.
18. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 2006;2: 385-397.
19. Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;2:328-334.
20. Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008;2:165-174.
21. Glintborg D, Andersen M, Richelsen B, Bruun JM. Plasma monocyte chemoattractant protein-1 (MCP-1) and macro-phage inflammatory protein-1a are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf) 2009;5:652-658.
22. Glintborg D, Stoving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, Flyvbjerg A, Andersen M. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;10:5605-5612.
23. Glintborg D, Hermann AP, Hagen C, Jensen LT, Frystyk J, Bennett P, Flyvbjerg A, Andersen M. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. Fertil Steril 2009;3:842-850.
24. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008;5: 1696-1701.
25. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;2:469-476.
26. Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril 2010;94:236-241.
27. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;4:1626-1632.
28. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;1:113-116.
29. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruoko-nen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;6:1266-1274.
30. Glintborg D, Hojlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF. Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab 2008;9: 3618-3626.
31. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;2:171-176.
32. Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycae-mic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 2004;8:859-866.
33. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;6:1255-1260.
34. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003;12:1594-1603.
35. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, Hermann AP. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006;2:337-345.
36. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, et al. Reduction of macrophage infiltration and chemoat-tractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005;8:2277-2286.
37. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Phar-macother 2008;7:1087-1108.
38. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;6:2728-2735.
39. Garcia-Rudaz MC, Ropelato MG, Escobar ME, Veldhuis JD, Barontini M. Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderli-ness of LH secretion in adolescents with polycystic ovary syndrome. Eur J Endocrinol 1998;6:621-630.
40. Balen AH. Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. Hum Reprod 1993;123-128.
41. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;1: 93-99.
42. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;9:617-623.
43. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production. J Clin Endocrinol Metab 2005;90:6099-6105.
44. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ, Chang RJ. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;12:5624-5631. (Pubitemid 38033025)
45. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993;2:273-274.
46. Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfutzner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol 2007;2:211-217.
47. DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, Chang RJ. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease. Fertil Steril 1985;4:453-459.
48. Moran C, Knochenhauer E, Boots LR, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 1999;4:671-674.
49. Carmina E, Gonzalez F, Chang L, Lobo RA. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol 1995;6:971-976.
50. Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab 2005;3:1347-1353.
51. Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril 1999;6:1075-1078.
52. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 1995;23:10619-10623.
53. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 a-reductase activity in polycystic ovary syndrome. Lancet 1990;8687:431-433.
54. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 2007;1:131-138.
55. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 a-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;6:2760-2766.
56. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5a-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 2003;12:5907-5913.
57. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 b-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000;3:533-539.
58. Draper N, Stewart PM. 11b-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005;2:251-271.
59. Walker BR, Rodin A, Taylor NF, Clayton RN. Endogenous inhibitors of 11b-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2000;1:77-80.
60. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R. Peroxisome prolif-erator-activated receptor-g ligands inhibit adipocyte 11b-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001;16:12629-12635.
61. Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebaek NE, Hilsted J, Skakkebae NE. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995;4:1407-1415.
62. Lanzone A, Villa P, Fulghesu AM, Pavone V, Caruso A, Mancuso S. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. Hum Reprod 1995;7:1653-1657.
63. Giudice LC. Growth factor action on ovarian function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;2:325-339, vi.
64. Cordido F, Peino R, Penalva A, Alvarez CV, Casanueva FF, Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab 1996;3:914-918.
65. Kopelman PG. Hormones and obesity. Baillieres Clin Endocrinol Metab 1994;3:549-575.
66. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004;5:337-375.
67. Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome. J Clin Endocrinol Metab 2001;11:5324-5329.
68. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003;2:99-104.
69. Cingel-Ristic V, Van Neck JW, Frystyk J, Drop SL, Flyvbjerg A. Administration of human insulin-like growth factor-binding protein-1 increases circulating levels of growth hormone in mice. Endocrinology 2004;9:4401-4407.
70. Haddad GF, Jodicke C, Thomas MA, Williams DB, Aubuchon M. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 2008;2:183-184.
71. Glintborg D, Andersen M, Hagen C, Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol (Oxf) 2005;6:683-691.
72. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 1992;3:779-782.
73. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet Med 2000;2: 124-129.
74. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;3:1226-1235.
75. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;1:401-406.
76. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;6:2669-2680.
77. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARg agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004;4:329-337.
78. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;9:3349-3354.
79. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;23:2427-2443.
80. Spanheimer R. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HOI) tablets for Type 2 diabetes mellitus. Internet home page 2007. Available from: URL: http://www.fda.gov/medwatch/safety/ 2007/Actosmar0807.pdf. Last accessed 25 May 2010.
81. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-g agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;4:1305-1310.
82. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009;9:e1000154.
83. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;15:1395-402.
84. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil TN, Guvener DN. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;9:3523-3530.
85. Schwartz AV, Cummings SR. Does rosiglitazone adversely affect bone formation and bone mineral density in post-menopausal women? Nat Clin Pract Endocrinol Metab 2007;3:622-623.
86. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;4:893-902.
87. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metfor-min versus rosiglitazone: a randomized study. Hum Reprod 2005;4:894-899.
88. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, Parra A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with poly-cystic ovary syndrome. J Clin Endocrinol Metab 2005;3: 1360-1365.
89. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, rteaga-Troncoso G, Parra A. Responses of serum androgen and insulin resistance to metformin and piogli-tazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;3:1360-1365. (Pubitemid 40463988)
90. Yilmaz M, Karakoc A, Toruner FB, Cakir N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in poly-cystic ovary syndrome. Gynecol Endocrinol 2005;3:154-160. (Pubitemid 41597556)
91. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005;12:3333-3340. (Pubitemid 41742509)
92. Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006;1:93-98.
93. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;4:402-410.
94. Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 2008;6:793-801.
95. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, Pfeifer M. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 2008;4:399-406.
96. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003;8:1618-1625.
97. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;1:CD005552.
98. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;1:1-50.
99. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;4:517-527.
100. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006;1:121-128.
101. Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;7:392-398.
102. Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2009;2:233-237.
103. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol 2008;6:596-609.
104. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009;92:1966-1982.